WuXi Biologics (Cayman) Inc 02269
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover 02269, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
WuXi Shares Fall as Washington Lobbying Group Cuts Ties
-
WuXi Companies' Shares Fall Amid Renewed U.S. Sanction Concerns
-
WuXi Companies' Shares Rise on Receding Worries About Potential U.S. Sanctions
-
WuXi Shares Hit by U.S. Committee Seeking Inquiry, Blacklisting
-
U.S. Lawmakers Seek Investigation Against China's WuXi AppTec — Update
-
WuXi Companies' Shares Slide Amid Concerns Over Proposed U.S. Bill
-
WuXi AppTec Shares Continue Slide After Company Calls U.S. Draft Bill Findings Inaccurate
-
WuXi AppTec Says Findings of U.S. Draft Bill Against Company Aren't Accurate
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 12,740
- Website
- https://www.wuxibiologics.com
Comparables
Valuation
|
Metric
|
02269
|
02181
|
02616
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 11.53 | 2.12 |
Price/Sales | — | 18.17 | 2.04 |
Price/Cash Flow | — | — | — |
Price/Earnings
02269
02181
02616
Financial Strength
|
Metric
|
02269
|
02181
|
02616
|
|---|---|---|---|
Quick Ratio | 1.79 | 0.69 | 1.42 |
Current Ratio | 2.20 | 1.08 | 1.56 |
Interest Coverage | 40.97 | −20.87 | −32.18 |
Quick Ratio
02269
02181
02616
Profitability
|
Metric
|
02269
|
02181
|
02616
|
|---|---|---|---|
Return on Assets (Normalized) | 9.91% | −20.43% | −38.51% |
Return on Equity (Normalized) | 14.09% | −79.65% | −157.15% |
Return on Invested Capital (Normalized) | 11.82% | −38.37% | −69.17% |
Return on Assets
02269
02181
02616
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nnzzldvhf | Hvn | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gmbhjwn | Hsgfd | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wdfgdkzj | Kxbjqn | $98.8 Bil | |
MRNA
| Moderna Inc | Fkknrvn | Kxx | $38.8 Bil | |
ARGX
| argenx SE ADR | Njvfclblp | Rpcn | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Pszxtfxk | Sdfr | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dvbcrnl | Gsnjbn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mmrvbrds | Rjybpsp | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mbyhpvvdk | Nfnhyr | $12.4 Bil | |
INCY
| Incyte Corp | Qdwrmsyq | Psfkfxx | $11.9 Bil |